Overview and Scope
Medical foods for orphan diseases refer to specialized nutritional products specifically formulated to meet the unique dietary needs of individuals affected by rare, genetic, or orphan diseases. These foods are used by patients suffering from rare orphan diseases.
Sizing and Forecast
The medical foods for orphan diseases market size has grown strongly in recent years. It will grow from $1.24 billion in 2023 to $1.33 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to orphan drug designation, research & development advances, government funding & grants, regulatory frameworks, improved diagnosis.
The medical foods for orphan diseases market size is expected to see strong growth in the next few years. It will grow to $1.7 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, healthcare system integration, emerging technologies in food science, precision nutrition, increased patient demand. Major trends in the forecast period include long-term efficacy studies, disease-specific formulations, education and training programs, focus on gut microbiome, nutritional supplements innovation.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/medical-foods-for-orphan-diseases-global-market-report
Segmentation & Regional Insights
The medical foods for orphan diseases market covered in this report is segmented –
1) By Product: Pills, Powder, Liquid, Other Products
2) By Route of Administration: Oral, Enteral
3) By Applications: Phenylketonuria, Tyrosinemia, Eosinophilic esophagitis, Food Protein-Induced Enterocolitis Syndrome (FPIES), Maple Syrup Urine Disease (MSUD), Homocystinuria, Other Applications
4) By Sales Channel: Online Sales, Institutional Sales, Retail Sales
North America was the largest region in the medical foods for orphan diseases market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical foods for orphan diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11940&type=smp
Major Driver Impacting Market Growth
The rising incidence of orphan diseases is expected to propel the growth of medical foods for the orphan diseases market going forward. Orphan disease, also known as a rare disease, is a medical condition that affects a relatively small number of individuals within a population. Medical foods are used to manage several orphan disorders to complete the specialized nutrition requirements of the patients. Hence, the rising incidence of orphan diseases contributes to the growth of the medical foods for orphan diseases market. For instance, in January 2023, according to the American Cancer Society, a US-based voluntary health organization, non-Hodgkin lymphoma, a rare disease, was one of the most common types of cancer in the United States and accounted for approximately 4% of cancer cases in 2023 where about 80,550 new diagnoses were estimated for 2023. Furthermore, in September 2022, according to a research study published by the National Library of Medicine, a US-based online medical library, the prevalence of idiopathic pulmonary fibrosis (IPF) was 36 per 100,000 people in 2021, and it has been increasing since 2016. Therefore, the increasing prevalence of orphan diseases is driving the medical foods for orphan diseases market.
Key Industry Players
Major companies operating in the medical foods for orphan diseases market report are Nestle S.A., Johnson & Johnson, Abbott Laboratories Inc., Danone S.A., Reckitt Benckiser Group plc., Ajinomoto Co. Inc., Meiji Holdings Co. Ltd., Fresenius Kabi AG, BioMarin Pharmaceutical Inc., Mead Johnson & Company LLC, Halyard Health, Alfasigma spA, Ultragenyx Pharmaceutical Inc., Immedica Group AB, Vitaflo International Ltd., Leadiant Biosciences Inc., Alcresta Therapeutics Inc., Marinus Pharmaceuticals Inc., Cambrooke Therapeutics Inc., Primus Pharmaceuticals Inc., Relief Therapeutics Holding AG, CANbridge Pharmaceuticals Inc., Ajinomoto Cambrooke Inc., Cerecin Inc., AMNIOX Medical Inc., Targeted Medical Pharma Inc., Solace Nutrition LLC, Orphan Therapeutics LLC, Metagenics Inc., Farma Genetics Inc.
The medical foods for orphan diseases market report table of contents includes:
1. Executive Summary
2. Medical Foods For Orphan Diseases Market Characteristics
3. Medical Foods For Orphan Diseases Market Trends And Strategies
4. Medical Foods For Orphan Diseases Market – Macro Economic Scenario
5. Global Medical Foods For Orphan Diseases Market Size and Growth
….
32. Global Medical Foods For Orphan Diseases Market Competitive Benchmarking
33. Global Medical Foods For Orphan Diseases Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Medical Foods For Orphan Diseases Market
35. Medical Foods For Orphan Diseases Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
